Your browser is no longer supported. Please, upgrade your browser.
Settings
IMDZ Immune Design Corp. daily Stock Chart
IMDZ [NASD]
Immune Design Corp.
Index- P/E- EPS (ttm)-1.14 Insider Own0.90% Shs Outstand48.09M Perf Week0.17%
Market Cap281.33M Forward P/E- EPS next Y-1.01 Insider Trans-68.18% Shs Float47.31M Perf Month306.25%
Income-53.10M PEG- EPS next Q-0.29 Inst Own81.70% Short Float1.16% Perf Quarter272.61%
Sales2.20M P/S127.88 EPS this Y3.50% Inst Trans5.72% Short Ratio0.53 Perf Half Y77.27%
Book/sh1.91 P/B3.06 EPS next Y8.20% ROA- Target Price5.88 Perf Year60.27%
Cash/sh1.99 P/C2.94 EPS next 5Y5.00% ROE- 52W Range1.10 - 5.85 Perf YTD350.00%
Dividend- P/FCF- EPS past 5Y- ROI-62.00% 52W High0.00% Beta3.46
Dividend %- Quick Ratio11.30 Sales past 5Y6.60% Gross Margin91.30% 52W Low431.82% ATR0.14
Employees55 Current Ratio11.30 Sales Q/Q0.00% Oper. Margin- RSI (14)93.55 Volatility0.27% 0.76%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.44 Prev Close5.84
ShortableYes LT Debt/Eq0.00 EarningsMar 27 AMC Payout- Avg Volume1.04M Price5.85
Recom2.80 SMA208.55% SMA5091.76% SMA20095.54% Volume460,765 Change0.17%
Oct-12-18Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $20
Sep-09-15Initiated Jefferies Buy
Mar-18-19 11:47AM  IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger GlobeNewswire
Mar-05-19 01:10PM  INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition PR Newswire
Feb-25-19 09:59AM  The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie Zacks
Feb-22-19 05:08PM  Merck to Buy Immunotherapy Developer Immune Design for $300M Zacks
12:20PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Immune Design Corp. - IMDZ ACCESSWIRE
11:14AM  Healthcare Stocks Leading the Sector ACCESSWIRE
09:27AM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Immune Design Corp. (IMDZ) on Behalf of Stockholders and Encourages IMDZ Investors to Contact the Firm GlobeNewswire
09:04AM  Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates Zacks
08:50AM  The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data Benzinga
Feb-21-19 10:15PM  IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger Business Wire +309.86%
04:54PM  Merck Plans $300 Million Acquisition Of Vaccine-Focused Biotech Investor's Business Daily
01:51PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp. PR Newswire
01:42PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Immune Design Corp. PR Newswire
10:10AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders GlobeNewswire
09:28AM  Merck To Buy Immune Design For $300M Benzinga
09:25AM  Tech Stocks to Watch Today ACCESSWIRE
08:20AM  Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal? PR Newswire
07:14AM  Merck to buy immunotherapy developer Immune Design for $300 mln Reuters
06:56AM  Merck to buy cancer drug developer Immune Design for $300 mln Reuters
06:45AM  Merck to Acquire Immune Design Business Wire
Dec-12-18 10:38AM  What Investors Should Know About Immune Design Corp.s (NASDAQ:IMDZ) Financial Strength Simply Wall St.
Dec-04-18 07:25AM  Detailed Research: Economic Perspectives on NanoString Technologies, Tyson Foods, Welbilt, Immune Design, Turning Point Brands, and LGI Homes What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-02-18 12:00PM  Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab GlobeNewswire
Nov-20-18 08:00AM  Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire
Nov-18-18 07:33AM  Edited Transcript of IMDZ earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 08:00AM  Immune Design to Present at Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-08-18 11:07AM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3 Zacks
Nov-06-18 06:30PM  Immune Design (IMDZ) Reports Q3 Loss, Lags Revenue Estimates Zacks -5.10%
05:24PM  Immune Design: 3Q Earnings Snapshot Associated Press
04:01PM  Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
08:01AM  Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting GlobeNewswire
Oct-30-18 08:00AM  Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update GlobeNewswire +11.85%
Oct-25-18 07:25AM  New Research Coverage Highlights Immune Design, QAD, Overseas Shipholding Group, Connecticut Water Service, Westport Fuel, and Monmouth Real Estate Investment Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-17-18 09:43AM  Peninsula biotech cuts jobs, shifts course after halting cancer vaccine trial American City Business Journals
Oct-16-18 02:43PM  Immune Design lays off workers and shifts course after halting lead cancer vaccine trial American City Business Journals
Oct-15-18 09:56AM  Immune Design to Halt Cancer Vaccine Program, Shares Plunge Zacks -7.57%
08:46AM  Implied Volatility Surging for Immune Design (IMDZ) Stock Options Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Immune Design and Histogenics ACCESSWIRE
Oct-12-18 05:27PM  Cancer vaccine developer restructures after axing lead drug trial American City Business Journals -33.69%
08:57AM  Immune Design's stock plummets toward record low after cancer vaccine program discontinued MarketWatch
07:34AM  The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Benzinga
Oct-11-18 04:01PM  Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305 GlobeNewswire
Oct-10-18 09:56AM  Could Immune Design Corps (NASDAQ:IMDZ) Investor Composition Impacts Your Returns? Simply Wall St. -5.03%
Sep-05-18 07:35AM  Investor Expectations to Drive Momentum within CSW Industrials, On Deck Capital, Hurco Companies, PetMed Express, Sandstorm Gold, and Immune Design Discovering Underlying Factors of Influence GlobeNewswire
Sep-04-18 09:42AM  Is Immune Design Corp (NASDAQ:IMDZ) Still A Cheap Healthcare Stock? Simply Wall St.
Sep-01-18 01:41AM  Immune Design (IMDZ) Down 2.8% Since Last Earnings Report: Can It Rebound? Zacks
Aug-30-18 08:00AM  Immune Design to Present at Upcoming September Investor Conferences GlobeNewswire
Aug-15-18 07:50AM  Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire -8.82%
Aug-02-18 10:19AM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2 Zacks
01:14AM  Edited Transcript of IMDZ earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-01-18 06:55PM  Immune Design (IMDZ) Reports Q2 Loss, Tops Revenue Estimates Zacks -6.58%
05:51PM  Immune Design: 2Q Earnings Snapshot Associated Press
04:01PM  Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-18 10:12AM  What's in Store for Immune Design (IMDZ) in Q2 Earnings? Zacks
Jul-25-18 08:00AM  Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update GlobeNewswire
Jun-25-18 08:00AM  Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma GlobeNewswire
Jun-01-18 08:00AM  Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference in New York GlobeNewswire
May-24-18 08:00AM  Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma GlobeNewswire
May-11-18 07:05AM  Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks ACCESSWIRE
May-09-18 03:55AM  Edited Transcript of IMDZ earnings conference call or presentation 2-May-18 8:30pm GMT Thomson Reuters StreetEvents +5.63%
May-03-18 01:27PM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1 Zacks
May-02-18 05:58PM  Immune Design: 1Q Earnings Snapshot Associated Press
04:01PM  Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Apr-26-18 10:11AM  What's in the Cards for Immune Design (IMDZ) in Q1 Earnings? Zacks
Apr-25-18 08:00AM  Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update GlobeNewswire
Apr-13-18 09:46AM  Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report? Zacks
Apr-02-18 07:55AM  Report: Developing Opportunities within VAREX IMAGING, Movado Group, Equity Bancshares, Huntington Ingalls Industries, Immune Design, and Westwood Holdings Group Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-21-18 05:34PM  Immune Design Corp (NASDAQ:IMDZ): Earnings To Drop Next Year, Is It A Long-Term Trend? Simply Wall St.
Mar-19-18 10:30AM  Immune Design Poised on Progress of Pipeline Candidates Zacks
Mar-15-18 12:01PM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4 Zacks -7.50%
09:11AM  Edited Transcript of IMDZ earnings conference call or presentation 14-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-14-18 04:19PM  Immune Design reports 4Q loss Associated Press
04:01PM  Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
08:54AM  Interested In Immune Design Corp (NASDAQ:IMDZ)? Heres How It Performed Recently Simply Wall St.
Mar-12-18 08:00AM  Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma GlobeNewswire +9.46%
Mar-07-18 08:00AM  Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update GlobeNewswire
Feb-26-18 09:12PM  What's in the Cards for Immune Design (IMDZ) in Q4 Earnings? Zacks
11:02AM  Best Growth Stock Picks Simply Wall St.
Feb-09-18 08:00AM  Immune Design to Present at Upcoming Investor Conferences GlobeNewswire
Jan-30-18 07:30AM  Consolidated Research: 2018 Summary Expectations for Immune Design, Primoris Services, Scotts Miracle-Gro, Heska, Calyxt, and Urstadt Biddle Properties Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-05-18 08:54AM  Why Immune Design (IMDZ) Could Beat Earnings Estimates Again Zacks
Dec-25-17 12:01PM  ETFs with exposure to Immune Design Corp. : December 25, 2017 Capital Cube
Dec-14-17 01:33PM  ETFs with exposure to Immune Design Corp. : December 14, 2017 Capital Cube
Dec-11-17 08:40AM  Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock Zacks -6.33%
Dec-10-17 09:00AM  Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients GlobeNewswire
Nov-24-17 10:42AM  ETFs with exposure to Immune Design Corp. : November 24, 2017 Capital Cube +9.41%
Nov-20-17 08:59AM  Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock Zacks -5.11%
Nov-13-17 12:35PM  ETFs with exposure to Immune Design Corp. : November 13, 2017 Capital Cube -11.11%
08:00AM  Immune Design to Present at Jefferies 2017 London Healthcare Conference GlobeNewswire
Nov-07-17 08:00AM  Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates GlobeNewswire
Nov-03-17 10:01AM  Immune Design Corp. :IMDZ-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube -7.78%
01:40AM  Edited Transcript of IMDZ earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-02-17 11:58AM  Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3 Zacks
Nov-01-17 05:51PM  Immune Design reports 3Q loss Associated Press -9.09%
04:02PM  Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
12:16PM  ETFs with exposure to Immune Design Corp. : November 1, 2017 Capital Cube
Oct-30-17 11:13AM  What's in the Cards for Immune Design (IMDZ) in Q3 Earnings? Zacks +12.20%
Oct-27-17 09:15AM  Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock Zacks
08:00AM  Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update GlobeNewswire
Oct-24-17 08:14PM  Immune Design Prices $80.0 Million Public Offering of Common Stock GlobeNewswire -16.35%
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paya Carlos VPresident and CEOJan 07Sale1.5813,01420,591156,576Jan 07 08:36 PM
ter Meulen Jan HenrikChief Scientific OfficerJan 07Sale1.593,4145,41583,982Jan 07 08:35 PM
Brady Stephen REVP, Strategy & FinanceJan 07Sale1.585,5168,72296,599Jan 07 08:33 PM
Yurasov SergeySr. VP, Clinic. Devel. & CMOJan 07Sale1.573,5225,53678,756Jan 07 08:34 PM
BVF PARTNERS L P/IL10% OwnerDec 04Sale1.83902,0001,653,907370,391Dec 04 09:59 PM